Record Net Revenue Growth
Net revenue rose 11% to $90 million in Q2 2026 compared to Q2 2025, with global medical cannabis revenue increasing 15% and international revenue increasing 22%.
Improved Adjusted Gross Margin
Consolidated adjusted gross margin improved 700 basis points to 61%, with the medical cannabis business consistently exceeding a 60% adjusted gross margin target, reaching 69% in Q2 2026.
Significant Increase in Adjusted EBITDA
Adjusted EBITDA rose more than 52% to $15 million, illustrating a strong focus on profitable and sustainable growth.
Strong International Market Position
Aurora is a market leader in Germany, Australia, Poland, and the U.K., and has a strong foothold in emerging markets with GMP-certified facilities in Canada and Germany.